Brokerages Anticipate Arrowhead Pharmaceuticals Inc (NASDAQ:ARWR) Will Post Quarterly Sales of $59.05 Million
Wall Street brokerages expect Arrowhead Pharmaceuticals Inc (NASDAQ:ARWR) to announce $59.05 million in sales for the current fiscal quarter, according to Zacks. Four analysts have provided estimates for Arrowhead Pharmaceuticals’ earnings, with estimates ranging from $36.00 million to $100.00 million. Arrowhead Pharmaceuticals posted sales of $730,000.00 in the same quarter last year, which suggests a positive year-over-year growth rate of 7,989%. The company is expected to issue its next quarterly earnings report on Tuesday, August 6th.
According to Zacks, analysts expect that Arrowhead Pharmaceuticals will report full-year sales of $168.62 million for the current financial year, with estimates ranging from $150.80 million to $207.81 million. For the next year, analysts expect that the company will report sales of $89.16 million, with estimates ranging from $40.00 million to $129.00 million. Zacks Investment Research’s sales averages are an average based on a survey of research analysts that that provide coverage for Arrowhead Pharmaceuticals.
Arrowhead Pharmaceuticals (NASDAQ:ARWR) last announced its quarterly earnings data on Wednesday, May 8th. The biotechnology company reported $0.24 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.22 by $0.02. The firm had revenue of $48.15 million during the quarter, compared to the consensus estimate of $45.78 million. Arrowhead Pharmaceuticals had a return on equity of 6.72% and a net margin of 10.09%.
Shares of ARWR traded down $0.31 during midday trading on Monday, reaching $25.82. 1,673,258 shares of the stock were exchanged, compared to its average volume of 3,485,751. Arrowhead Pharmaceuticals has a 12-month low of $10.41 and a 12-month high of $27.69. The company has a market capitalization of $2.48 billion, a PE ratio of -39.72 and a beta of 1.67.
In other news, General Counsel Patrick O’brien sold 30,000 shares of the stock in a transaction dated Tuesday, May 28th. The stock was sold at an average price of $24.88, for a total transaction of $746,400.00. Following the transaction, the general counsel now owns 203,000 shares of the company’s stock, valued at approximately $5,050,640. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, CEO Christopher Richard Anzalone sold 50,000 shares of the stock in a transaction dated Wednesday, April 3rd. The shares were sold at an average price of $19.30, for a total value of $965,000.00. The disclosure for this sale can be found here. In the last three months, insiders have sold 107,071 shares of company stock worth $2,306,962. 4.80% of the stock is currently owned by insiders.
Several hedge funds and other institutional investors have recently modified their holdings of ARWR. Perceptive Advisors LLC lifted its position in shares of Arrowhead Pharmaceuticals by 10.2% during the 1st quarter. Perceptive Advisors LLC now owns 330,738 shares of the biotechnology company’s stock worth $6,069,000 after buying an additional 30,738 shares during the period. Jane Street Group LLC lifted its position in shares of Arrowhead Pharmaceuticals by 181.1% during the 1st quarter. Jane Street Group LLC now owns 46,052 shares of the biotechnology company’s stock worth $845,000 after buying an additional 29,667 shares during the period. Morgan Stanley lifted its position in shares of Arrowhead Pharmaceuticals by 27.4% during the 1st quarter. Morgan Stanley now owns 266,817 shares of the biotechnology company’s stock worth $4,896,000 after buying an additional 57,418 shares during the period. Voya Investment Management LLC lifted its position in shares of Arrowhead Pharmaceuticals by 2.9% during the 1st quarter. Voya Investment Management LLC now owns 37,212 shares of the biotechnology company’s stock worth $683,000 after buying an additional 1,063 shares during the period. Finally, Geode Capital Management LLC lifted its position in shares of Arrowhead Pharmaceuticals by 16.7% during the 1st quarter. Geode Capital Management LLC now owns 1,162,703 shares of the biotechnology company’s stock worth $21,335,000 after buying an additional 166,245 shares during the period. 62.31% of the stock is currently owned by institutional investors and hedge funds.
About Arrowhead Pharmaceuticals
Arrowhead Pharmaceuticals, Inc develops medicines for the treatment of intractable diseases in the United States. The company's pipeline include ARO-AAT, a RNA interference (RNAi) therapeutic candidate for the treatment of liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3 to treat hypertriglyceridemia; ARO-ANG3 to reduce production of angiopoietin-like protein 3; ARO-ENaC to reduce production of the epithelial sodium channel alpha subunit in the airways of the lung; and ARO-HIF2 for the treatment of clear cell renal cell carcinoma.
Featured Article: Treasury Bonds
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Arrowhead Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arrowhead Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.